SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]
Kim H, Tangen C, Vaishampayan U, Tripathi A, Patel S, Shuch B, Barata P, Tan A, Esfeller L, Lara P, Sanchez A, Lerner S, Thompson I. SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars And Original Investigations 2024, 42: s4. DOI: 10.1016/j.urolonc.2024.01.044.Peer-Reviewed Original ResearchCytoreductive nephrectomyPrimary tumorImmune checkpointsSystemic therapySurvival outcomesTrials of immune checkpoint inhibitorsHigher neoantigen loadPROBE study designImmune checkpoint inhibitorsSynchronous primary tumorsAdvanced renal cancerWeeks of therapyOverall survival outcomesShorter survival outcomeStandard of careCARMENA trialNeoantigen loadSunitinib therapyAdvanced RCCAntigen spreadingImmune therapyUrologic evaluationFrontline settingCombination therapySurgical candidates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply